Audiologists have known about the ototoxicity of quinine (and its derivatives) and antibiotics (macrolide and aminoglycoside) for decades. But we have never seen the combined use of two drugs, each with known ototoxic potential, being used as an intervention strategy for the coronavirus pandemic (COVID-19).
In an effort to combat the coronavirus (COVID-19), front-line physicians are repurposing two drugs: hydroxychloroquine (commonly used for malaria and rheumatoid arthritis) and azithromycin (a macrolide antibiotic used to treat common infections of the respiratory system, the ear and the eye). Both drugs are known ototoxic agents; however, there is no published research about the synergistic ototoxic effects of these drugs in treating COVID-19.
At the present time, it is not known if hearing loss and/or tinnitus will be a late onset side effect of this COVID-19 drug intervention. Therefore, case history questions will need to be added to accommodate this new population of patients.
Recent Posts
Medicaid in Focus: What Audiologists Need to Know Now
With the recent changes to Medicaid, the Academy is preparing audiologists with the new one-pager, “Audiology in Medicaid”, an exclusive member resource designed to educate on…
American Academy of Audiology Clinical Consensus Statement: Assessment of Vestibular Function in the Pediatric Population
Authors: Violette Lavender, AuD, Kristen Janky, PhD, Katheryn Bachmann, PhD, Melissa Caine, AuD, Micheal Castiglione, AuD, Guangwei Zhou, ScD The American Academy of Audiology Clinical…
CMS Releases CY 2026 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Proposed Rule
On July 15, the Centers for Medicare and Medicaid Services (CMS) released the calendar year (CY) 2026 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed rule,…